AstraZeneca's COVID Vaccine On Hold: A Reminder Drug Development Is Never Straightforward

The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.

Stop barrier — AZ/Oxford vaccine on hold • Source: Shutterstock

AstraZeneca PLC and the University of Oxford have put a voluntary clinical trial hold on the Phase III trial testing their COVID-19 vaccine due to an adverse event. The companies confirmed the move in the evening on 8 September, only about a week after initiating the Phase III trial in the US.

While the development of several COVID-19 vaccines across the industry has been moving at an unprecedented pace and remarkably smoothly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

30 May 2025

• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

21 May 2025

• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

17 Feb 2025

• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

20 Jan 2025

• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.